Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2019 · 10-Q
Revenue$101.71M$101.71M+50.1% vs Q2 2018 Net Income$1.99M$1.99MN/M vs Q2 2018 EPS Diluted$0.02$0.02−71.4% vs Q2 2018 Gross Profit$48,966,000+60.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,721,000N/M Free Cash Flowderived-$8,162,000N/M Margins · derivedGross margin48.1%+3.1 pt vs Q2 2018
Operating margin4.4%+3.2 pt vs Q2 2018
Net margin2.0%+2.5 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 7, 2019 · 38 d after period end